Retinopathy of Prematurity Market Share

North American Market Forecast

Retinopathy of prematurity market in North America region is anticipated to hold the largest share of about 41% by the end of 2036. The regional growth is attributed to ongoing advancements in medical technology, a focus on early detection and intervention, and a commitment to improving outcomes for premature infants at risk of developing retinopathy of prematurity. In addition, growing awareness among people regarding neonatal imaging is further expected to propel the growth of the regional market. Moreover, AI is highly being used for the diagnosis of retinopathy of prematurity in newborns. According to Pharmaceutical Technology, nearly 80% of infants treated with Eylea experienced an absence of active retinopathy of prematurity and unfavorable structural outcomes at 52 weeks of age in both trials. AI in healthcare has effectively diagnosed a blindness-causing disease in premature newborns which led to growth in the market.

European Market Analysis

The Europe market is estimated to be the second largest, registering a share of about 35% by the end of 2036. The market’s expansion can be attributed to the patient-centric approach in which the shift towards patient-centric healthcare models such as gathering feedback from patient’s families allows healthcare providers to continuously improve services, adopt better strategies, and emphasize personalized treatment plans contributing to the growth of retinopathy of prematurity market in Europe. Moreover, healthcare providers in Europe aim to create personalized treatment plans based on the specific needs of each premature infant diagnosed with retinopathy of prematurity which further stimulates the market. In addition, efforts to standardize treatment protocols and guidelines for retinopathy of prematurity management ensure consistency in healthcare practices, driving market growth in the region through streamlined approaches.